Keywords: alpharx, selects, arx82, advanced, preclin, development, canada

AlphaRx selects ARX82 for advanced preclin development

Article | 24 September 2007

Canada's AlphaRx, a specialty pharmaceutical company, says that its ARX828, an orally-administered, potent and selective inhibitor of inducible nitric oxide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Dexamethasone

Decadron

Indocin

Indomethacin

Inomax

Go to drug listing